AI & Technical question
Abridge has a post-training approach that uses clinician edits, final notes, and EHR context to improve note generation. How would you define the hypotheses, stage gates, and success metrics to take it from offline research to shadow mode to a limited production launch? What evidence would be required at each step to continue, pause, or kill the effort?
- Abridge
- AI & Technical
- Hard
Practice this question out loud. An AI interviewer asks it, follows up like a real interviewer would, and scores your answer. Type or speak.
Start a mock interview on this question · Mock interview from a job description
What this question tests
Tests designing staged evidence-gated rollout, offline research to shadow mode to limited production, for a post-training approach in a clinical setting.
How to approach it
- Offline research stage: hypothesize that clinician edits and final signed notes can improve note quality, and validate on a held-out historical dataset against an accuracy and completeness benchmark.
- Set the gate to advance: offline improvement must exceed a meaningful margin over the current model on the benchmark, not just be statistically nonzero.
- Shadow mode stage: run the post-trained model in parallel with production on live cases without surfacing output to clinicians, and compare its outputs against actual clinician-edited notes.
- Set the gate to advance: shadow mode outputs must match or exceed production quality across note types and specialties, with no new failure modes introduced.
- Limited production stage: roll out to a small clinician group with explicit monitoring for edit rate, time saved, and any safety-relevant errors, with an easy opt-out.
- Set the kill criteria at every stage: any safety-relevant regression or bias found by specialty or note type pauses the rollout regardless of aggregate metrics.
What a strong answer includes
- Defines specific, escalating evidence bars at each gate rather than one blanket quality threshold for the whole rollout.
- Uses shadow mode specifically to catch new failure modes before any clinician sees the output, a distinct step from offline testing.
- Sets a kill criterion tied to safety regression by segment, not just aggregate score, since averages can hide harm to a subgroup.
- Gives limited production clinicians an explicit opt-out, treating trust as part of the success criteria, not just accuracy.
Common mistakes
- Using one aggregate quality metric across all stages instead of segment-level safety checks.
- Skipping shadow mode and going straight from offline results to a clinician-facing pilot.
- Treating a kill decision as purely a leadership call rather than defining objective triggers in advance.
Likely follow-up questions
- What specific bias or failure mode would concern you most in shadow mode?
- How would you decide whether a regression in one specialty should halt the whole rollout?
More ai & technical questions
- For a model that turns patient-clinician conversations into structured clinical notes, what evaluation suite would you use beyond aggregate quality scores? Specify the failure modes you would prioritize, how you would segment risk by workflow or note type, and the thresholds or escalation paths you would require before declaring the model safe enough to scale.Abridge · AI & Technical · Hard
- Abridge has access to de-identified conversations, clinician edits, final signed notes, EHR context, and downstream care actions, but each signal differs in coverage, cost, bias, and clinical relevance. How would you prioritize which signals to use first for post-training, and what framework would you use to decide whether a sparse, subjective, or expensive signal is still worth operationalizing?Abridge · AI & Technical · Hard
- A chart-aware CDS assistant must feel fast enough for live clinical use while staying reliable and evidence-grounded. How would you work with engineering and ML to define the system tradeoffs and product requirements around latency, retrieval quality, grounding, fallback behavior, and failure handling, and what technical or model-level changes would you prioritize first if response time improved only by reducing answer quality?Abridge · AI & Technical · Hard
- Abridge has a new AI-assisted clinician workflow whose model quality is improving but still imperfect. What launch criteria would you set before exposing it in live care, how would you combine offline evals, human review, and UX guardrails, and how would you phase the rollout to manage clinical and compliance risk?Abridge · AI & Technical · Hard
- Production monitoring shows a model improves average note quality but increases rare critical errors. How would you investigate whether this is a measurement artifact, a distribution shift, or a real safety regression, and how would you decide between shipping, pausing, rolling back, or narrowing scope?Abridge · AI & Technical · Hard
- Abridge explicitly uses LLM judges, rule-based evaluators, human annotation, and online monitoring. How would you decide which of these methods belongs at each stage of the eval lifecycle, and what failure modes, cost/speed tradeoffs, and confidence limits would you communicate before teams rely on them for launch decisions?Abridge · AI & Technical · Hard
More questions from Abridge
Learn the skill behind it
Chapters of the AI PM course that teach what this question tests.
- Chapter 1: Foundations: the model and the decisions it forces on you
- Chapter 8: Evals: define good and make the number defensible
- Chapter 6: Agents and agentic architecture